Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines.
Ontology highlight
ABSTRACT: A large number of studies are being conducted to evaluate the efficacy and safety of candidate vaccines against coronavirus disease 2019 (COVID-19). Most phase 3 trials have adopted virologically confirmed symptomatic COVID-19 as the primary efficacy end point, although laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is also of interest. In addition, it is important to evaluate the effect of vaccination on disease severity. To provide a full picture of vaccine efficacy and make efficient use of available data, we propose using SARS-CoV-2 infection, symptomatic COVID-19, and severe COVID-19 as dual or triple primary end points. We demonstrate the advantages of this strategy through realistic simulation studies. Finally, we show how this approach can provide
SUBMITTER: Lin DY
PROVIDER: S-EPMC7799296 | biostudies-literature | 2021 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA